| P50 | author | Mari Luz Hernández | Q68297042 |
| P2093 | author name string | Javier Fernández-Ruiz | |
| | José A Ramos | |
| P2860 | cites work | The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive | Q73180328 |
| | Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice | Q73264277 |
| | Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients | Q73531406 |
| | Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys | Q80609691 |
| | Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes | Q84093381 |
| | Dopamine and reward: The anhedonia hypothesis 30 years on | Q22252806 |
| | Cannabinoids in health and disease | Q24633884 |
| | Gene-environment interplay between cannabis and psychosis | Q24643510 |
| | Endocannabinoids in the retina: from marijuana to neuroprotection | Q24656049 |
| | Looking for the role of cannabinoid receptor heteromers in striatal function | Q24658338 |
| | Marijuana and cannabinoid regulation of brain reward circuits | Q24671514 |
| | Endocannabinoid signalling in the blood of patients with schizophrenia | Q24800061 |
| | Role of endogenous cannabinoids in synaptic signaling | Q28185075 |
| | Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 |
| | CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia | Q28206825 |
| | Dopamine and the regulation of cognition and attention | Q28215209 |
| | Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1 | Q28216128 |
| | N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors | Q28244889 |
| | Antioxidant and neuroprotective properties of N-arachidonoyldopamine | Q28260510 |
| | Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis | Q28268078 |
| | Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons | Q28272251 |
| | Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia | Q28285577 |
| | Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction | Q28363073 |
| | Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme | Q28372132 |
| | Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 |
| | Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. | Q31813503 |
| | Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse | Q31863511 |
| | Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens | Q31877443 |
| | Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study | Q72656516 |
| | Tetrahydrocannabinol potentiates reserpine-induced hypokinesia | Q72916142 |
| | Elevated endogenous cannabinoids in schizophrenia | Q73029596 |
| | Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains | Q37264478 |
| | The endocannabinoid system in Huntington's disease. | Q37264872 |
| | Endocannabinoid-mediated control of synaptic transmission | Q37363621 |
| | The basal ganglia in Parkinson's disease: current concepts and unexplained observations | Q37363923 |
| | WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. | Q37371387 |
| | The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine | Q37376434 |
| | Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation | Q37382150 |
| | The endocannabinoid system as a target for the treatment of motor dysfunction | Q37394164 |
| | Endocannabinoids and reproductive endocrinology. | Q37428969 |
| | Basic neuroanatomy and neuropharmacology of cannabinoids | Q37444802 |
| | Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders | Q37444808 |
| | Cannabinoids and appetite: food craving and food pleasure | Q37444818 |
| | Cannabinoids and Parkinson's disease. | Q37617450 |
| | Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 |
| | The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons | Q40069031 |
| | Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 |
| | Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. | Q40799260 |
| | Marijuana for parkinsonian tremor | Q41369366 |
| | Cannabis and neuroleptic agents in schizophrenia | Q41535630 |
| | Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 |
| | Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study | Q42492989 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. | Q42517324 |
| | Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Q42520647 |
| | Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats | Q42536101 |
| | Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. | Q42624110 |
| | Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease | Q42695373 |
| | Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats | Q43425029 |
| | Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 |
| | Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids | Q43517979 |
| | Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. | Q43581230 |
| | Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. | Q43621342 |
| | Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 |
| | Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation | Q43698135 |
| | Cannabis induced dopamine release: an in-vivo SPECT study | Q43744306 |
| | A cannabinoid mechanism in relapse to cocaine seeking. | Q43759232 |
| | Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 |
| | Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. | Q43873792 |
| | Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels | Q43890403 |
| | Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats | Q44014660 |
| | Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids | Q44051647 |
| | Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 |
| | Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study | Q44182591 |
| | Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. | Q44182704 |
| | Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine | Q44189376 |
| | SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats | Q44190296 |
| | Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens | Q44299680 |
| | Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism | Q44346123 |
| | Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum | Q44385248 |
| | Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats | Q44386037 |
| | Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. | Q44413284 |
| | Effects of SR141716A on ethanol and sucrose self-administration | Q32117915 |
| | Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. | Q33186390 |
| | The role of the endogenous cannabinoid system in drug addiction | Q33344540 |
| | Motor actions of cannabinoids in the basal ganglia output nuclei | Q33720160 |
| | The endogenous cannabinoid system and brain development | Q33815201 |
| | Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia | Q33932087 |
| | Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial | Q33958602 |
| | Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. | Q33965686 |
| | Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug | Q33995048 |
| | A missense mutation in human fatty acid amide hydrolase associated with problem drug use. | Q34032872 |
| | Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia | Q34113369 |
| | The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism. | Q34181090 |
| | Cannabis and the brain | Q34199483 |
| | Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol | Q34254854 |
| | Cannabinoids reduce symptoms of Tourette’s syndrome | Q34266671 |
| | Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms | Q34349067 |
| | Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 |
| | Modulation of transmitter release via presynaptic cannabinoid receptors | Q34430714 |
| | Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice | Q34431882 |
| | Involvement of the endocannabinoid system in drug addiction | Q34495242 |
| | Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study | Q34524477 |
| | Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 |
| | Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. | Q34605939 |
| | Endocannabinoids and immune regulation | Q34607419 |
| | Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression | Q34609936 |
| | The endocannabinoid system and pain | Q34612917 |
| | Levodopa-induced dyskinesias | Q34618170 |
| | Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. | Q34673177 |
| | The role of endocannabinoids in the hypothalamic regulation of visceral function | Q34673192 |
| | Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 |
| | Mesolimbic dopaminergic decline after cannabinoid withdrawal | Q34750833 |
| | What is the mechanism whereby cannabis use increases risk of psychosis? | Q34900815 |
| | Can recreational doses of THC produce significant dopamine release in the human striatum? | Q34987781 |
| | The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions | Q35045001 |
| | CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 |
| | Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human | Q35120095 |
| | Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors | Q35202878 |
| | The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders | Q35586641 |
| | Endocannabinoid signaling and long-term synaptic plasticity. | Q35679432 |
| | Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. | Q35938826 |
| | Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. | Q36119168 |
| | Cannabinoid tolerance and dependence: a review of studies in laboratory animals | Q36140875 |
| | CB1 receptor antagonists for the treatment of nicotine addiction | Q36151299 |
| | Endocannabinoid signaling system and brain reward: emphasis on dopamine | Q36152336 |
| | Dopaminergic neurones: much more than dopamine? | Q36198137 |
| | The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? | Q36228755 |
| | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 |
| | Expanding treatment of tobacco dependence | Q36282260 |
| | Endocannabinoids and the haematological system | Q36358723 |
| | Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders | Q36425951 |
| | Cannabinoids and prefrontal cortical function: insights from preclinical studies | Q36436004 |
| | Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. | Q36441179 |
| | Cannabinoid control of motor function at the basal ganglia. | Q36441208 |
| | The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction | Q36478275 |
| | Endocannabinoids and the control of energy balance | Q36671574 |
| | Cannabis use and the risk of developing a psychotic disorder | Q36713971 |
| | The endocannabinoid system in brain reward processes | Q36741861 |
| | Biochemistry and pharmacology of endovanilloids | Q36756199 |
| | Cannabinoids and psychosis | Q36756388 |
| | Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? | Q36784126 |
| | The endocannabinoid system and gut-brain signalling. | Q36955435 |
| | The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence | Q36977773 |
| | Presynaptic modulation by endocannabinoids | Q37026723 |
| | Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice | Q37060812 |
| | Neurobiological mechanisms of cannabinoid addiction. | Q37121224 |
| | D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling | Q37130639 |
| | Targeting the endocannabinoid system: to enhance or reduce? | Q37150745 |
| | Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond | Q37164807 |
| | Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism | Q44418544 |
| | Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors | Q44418969 |
| | Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats | Q44444449 |
| | Neuromorphological background of cannabis addiction | Q44494962 |
| | Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats | Q44506503 |
| | Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 |
| | Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. | Q44723162 |
| | Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia | Q44748286 |
| | Effects of anandamide and morphine combinations on memory consolidation in cd1 mice: involvement of dopaminergic mechanisms. | Q44780307 |
| | Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder | Q44915184 |
| | Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 |
| | Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse | Q45004332 |
| | Delta9-tetrahydrocannabinol improves motor control in a patient with musician's dystonia | Q45010982 |
| | Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms | Q45049153 |
| | Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 |
| | Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. | Q45932602 |
| | Effects of cannabinoids infused into the dorsal hippocampus upon memory formation in 3-days apomorphine-treated rats. | Q46007120 |
| | Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens. | Q46018366 |
| | Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. | Q46023513 |
| | The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. | Q46026291 |
| | CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors | Q46179251 |
| | Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors | Q46184685 |
| | N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. | Q46187005 |
| | Cannabinoid receptors in the bed nucleus of the stria terminalis control cortical excitation of midbrain dopamine cells in vivo | Q46314846 |
| | Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 |
| | Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum | Q46406572 |
| | Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 |
| | High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 |
| | Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial | Q46595361 |
| | CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats | Q46677665 |
| | Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications | Q46731448 |
| | The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats | Q46870466 |
| | Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. | Q47242856 |
| | Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro | Q48127886 |
| | Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol | Q48141521 |
| | Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. | Q48217036 |
| | Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. | Q48254078 |
| | Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function | Q48262881 |
| | Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. | Q48273440 |
| | Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 |
| | Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. | Q48364989 |
| | Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids | Q48383234 |
| | Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient | Q48443035 |
| | Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. | Q48445359 |
| | Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia | Q48532654 |
| | Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release | Q48656612 |
| | (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. | Q51915805 |
| | Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists | Q71293074 |
| P433 | issue | 3 | |
| P921 | main subject | dopamine | Q170304 |
| | cannabinoids | Q422936 |
| | pathophysiology | Q1135939 |
| P304 | page(s) | e72-91 | |
| P577 | publication date | 2010-04-12 | |
| P1433 | published in | CNS Neuroscience & Therapeutics | Q5013184 |
| P1476 | title | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders | |
| P478 | volume | 16 | |